• Report store
  • PVSRIPO Emerging Drug Insight and Market Forecast − 2032
PVSRIPO Emerging Drug Insight Report
PVSRIPO Emerging Drug Insight Report
PVSRIPO Emerging Drug Insight and Market Forecast − 2032

  • Published Date : Jun 2023

  • Pages : 30

  • Delivery Time : 48 Hours

  • Region : United States, EU5, Japan

PVSRIPO Emerging Drug Insight

“PVSRIPO Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about PVSRIPO for Oncolytic Virus Therapies (OVTs) in the seven major markets. A detailed picture of the PVSRIPO for OVTs in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the PVSRIPO for OVTs. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PVSRIPO market forecast analysis for OVTs in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in OVTs.

Drug Summary

Lerapolturev (formerly Known as PVSRIPO) is a recombinant, live attenuated, nonpathogenic OV containing the oral poliovirus Sabin Type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus Type 2 (HRV2), with potential antineoplastic activity. The poliovirus is selectively absorbed upon intratumoral administration of recombinant oncolytic poliovirus PVS-RIPO. It replicates in tumor cells expressing CD155 (poliovirus receptor, PVR, or NECL5), causing tumor cell lysis. CD155, an oncofetal cell adhesion molecule and tumor antigen, is ectopically expressed in certain cancers, such as glioblastoma multiforme (GMB), and plays a vital role in tumor cell migration, invasion, and metastasis. Due to the heterologous HRV2 IRES in this recombinant virus, PVS-RIPO only propagates in susceptible, non-neuronal cells (e.g., GBM). It is the only OV that is not destroyed by the Type 1 interferon response caused by these viruses.

The company is progressing clinical research on multiple fronts with the powerful, versatile Lerapolturev technology. A Phase II clinical study in recurrent glioblastoma multiforme (rGBM) is being studied. The LUMINOS-101 Phase II clinical trial assessing PVSRIPO in combination with pembrolizumab in patients with rGBM enrolled its first patient in November 2020.

The LUMINOS-102 Phase II study investigating PVSRIPO alone or in combination with a PD-1 inhibitor in patients with treatment-refractory melanoma received IND clearance in November 2020 and has started enrolling patients.

Scope of the Report

The report provides insights into:

  • A comprehensive product overview including the PVSRIPO description, mechanism of action, dosage and administration, research and development activities in OVTs.
  • Elaborated details on PVSRIPO regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the PVSRIPO research and development activities in OVTs across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around PVSRIPO.
  • The report contains forecasted sales of for OVTs till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for OVTs.
  • The report also features the SWOT analysis with analyst views for PVSRIPO in OVTs.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PVSRIPO Analytical Perspective by DelveInsight

In-depth PVSRIPO Market Assessment

This report provides a detailed market assessment of PVSRIPO for OVTs in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

PVSRIPO Clinical Assessment

The report provides the clinical trials information of PVSRIPO for OVTs covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for OVTs is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PVSRIPO dominance.
  • Other emerging products for OVTs are expected to give tough market competition to PVSRIPO and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PVSRIPO in OVTs.
  • Our in-depth analysis of the forecasted sales data of PVSRIPO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PVSRIPO in OVTs.

Key Questions

  • What is the product type, route of administration and mechanism of action of PVSRIPO?
  • What is the clinical trial status of the study related to PVSRIPO in OVTs and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PVSRIPO development?
  • What are the key designations that have been granted to PVSRIPO for OVTs?
  • What is the forecasted market scenario of PVSRIPO for OVTs?
  • What are the forecasted sales of PVSRIPO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how are these giving competition to PVSRIPO for OVTs?
  • Which are the late-stage emerging therapies under development for the treatment of OVTs?

1. Report Introduction

2. PVSRIPO Overview in OVTs

2.1. Product Detail

2.2. Clinical Development

2.2.1. Clinical studies

2.2.2. Clinical trials information

2.2.3. Safety and efficacy

2.3. Other Developmental Activities

2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. PVSRIPO Market Assessment

5.1. Market Outlook of PVSRIPO in OVTs

5.2. 7MM Analysis

5.2.1. Market Size of PVSRIPO in the 7MM for OVTs

5.3. Country-wise Market Analysis

5.3.1. Market Size of PVSRIPO in the United States for OVTs

5.3.2. Market Size of PVSRIPO in Germany for OVTs

5.3.3. Market Size of PVSRIPO in France for OVTs

5.3.4. Market Size of PVSRIPO in Italy for OVTs

5.3.5. Market Size of PVSRIPO in Spain for OVTs

5.3.6. Market Size of PVSRIPO in the United Kingdom for OVTs

5.3.7. Market Size of PVSRIPO in Japan for OVTs

6. SWOT Analysis

7. Analysts’ Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables:

    Table 1: PVSRIPO, Clinical Trial Description, 2023

    Table 2: PVSRIPO, General Description

    Table 3: Competitive Landscape (Marketed Therapies)

    Table 4: Competitive Landscape (Emerging Therapies)

    Table 5: PVSRIPO Market Size in the 7MM, in USD million (2019–2032)

    Table 6: PVSRIPO Market Size in the US, in USD million (2019–2032)

    Table 7: PVSRIPO Market Size in Germany, in USD million (2019–2032)

    Table 8: PVSRIPO Market Size in France, in USD million (2019–2032)

    Table 9: PVSRIPO Market Size in Italy, in USD million (2019–2032)

    Table 10: PVSRIPO Market Size in Spain, in USD million (2019–2032)

    Table 11: PVSRIPO Market Size in the UK, in USD million (2019–2032)

    Table 12: PVSRIPO Market Size in Japan, in USD million (2019–2032)

List of Figures:

    Figure 1: PVSRIPO Market Size in the 7MM, USD million (2019–2032)

    Figure 2: PVSRIPO Market Size in the United States, USD million (2019–2032)

    Figure 3: PVSRIPO Market Size in Germany, USD million (2019–2032)

    Figure 4: PVSRIPO Market Size in France, USD million (2019–2032)

    Figure 5: PVSRIPO Market Size in Italy, USD million (2019–2032)

    Figure 6: PVSRIPO Market Size in Spain, USD million (2019–2032)

    Figure 7: PVSRIPO Market Size in the United Kingdom, USD million (2019–2032)

    Figure 8: PVSRIPO Market Size in Japan, USD million (2019–2032)

Tags:

loader

Request Sample

View Pricing